HUTCHMED (LON:HCM) Shares Down 3.7% – Here’s Why

Shares of HUTCHMED (China) Limited (LON:HCM) dropped 3.7% during mid-day trading on Wednesday . The stock traded as low as GBX 258 ($3.26) and last traded at GBX 260 ($3.28). Approximately 44,821 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 88,241 shares. The stock had previously closed at GBX 270 ($3.41).

HUTCHMED Trading Down 1.6 %

The firm has a 50 day moving average of GBX 287.36 and a 200-day moving average of GBX 283.59. The company has a quick ratio of 2.97, a current ratio of 2.81 and a debt-to-equity ratio of 11.78. The firm has a market capitalization of £2.11 billion, a P/E ratio of -6,425.00 and a beta of 0.76.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.